TremelImumab aNd durvalumab combination For the non-operatIve management (NOM) of Microsatellite InstabiliTY (MSI)-high resectable gastric or gastroesophageal junction cancer: The multicentre, single-arm, multi-cohort, Phase II INFINITY study. - Infinity

G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST0 个研究点目标入组 31 人开始时间: 2021年5月24日最近更新: 2021年8月30日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 31

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Written informed consent and any locally required authorization (such as the European Union [EU] Data Privacy Directive) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
•2.Age = 18 years old.
•3.ECOG Performance Status 0-1.
•4.Body weight >30 kg.
•5.Diagnosis of resectable gastric or gastroesophageal junction (Siewert II-III) cancer, categorized according to TNM classification 8th edition:
•cT = 2, any cN, M0
•Any cT, cN1-3, M0
•6.Absence of distant metastases as defined by negativity of computed tomography (CT) and 18-fluorodeoxyglucose positron-emission tomography (18-FDG PET).
•7.Life expectancy of at least 12 weeks
•8.MSI-high and dMMR status confirmed by IHC and multiplex PCR, and EBV-negative status by ISH, as determined centrally at the Co-ordinating Centre.
•9.Adequate bone marrow and organ function, as defined by laboratory tests:
•a.Neutrophil count = 1.5 x 103/µL
•b.Platelet count = 100 x 106/µL
•c.Haemoglobin = 9 g/dL
•d.Total bilirubin lower than 1.5 time the upper-normal limits (ULN) of the Institutional normal values
•e.AST (SGOT) and/or ALT (SGPT) < 2.5 x ULN
•f.Creatinine clearance (calculated according to Cockroft and Gault) > 40 mL/min or serum creatinine < 1.5 x ULN.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 11
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

排除标准

•1.Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site)
•2.Previous enrolment in the present study
•3.Participation in another clinical study with an investigational product during the last 12 months
•4.Signs of distant metastases.
•5.Prior medical treatments or irradiation for gastric cancer.
•6.Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
•7.Previous treatments with immune checkpoint inhibitors targeting CTLA4, including tremelimumab, PD-1 or PD-L1, including durvalumab.
•8.History of allergy or severe hypersensitivity reaction to monoclonal antibodies.
•9.History of autoimmune diseases or history of organ transplantation that require immunosuppressive therapy. The following are exceptions to this criterion:
•Patients with vitiligo or alopecia
•Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
•Any chronic skin condition that does not require systemic therapy
•Patients with celiac disease controlled by diet alone
•10.History of active primary immunodeficiency Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA
•11.Any condition requiring systemic treatment with corticosteroids at doses equal or superior to 10 mg daily of prednisone or equivalents, or other immunosuppressive drugs within 14 days from the inclusion in the study. The following medications are exceptions to this criterion:
•Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)
•Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
•Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
•12.Administration of live vaccines within 4 weeks from the inclusion in the study. Note: Patients, if enrolled, should not receive live vaccine while receiving study drug(s) and up to 30 days after the last dose of study drug(s).
•13.History of allogenic organ transplantation
•14.Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
•15.Women in pregnancy or lactation condition. Women with child-bearing potential or sexually-active men not willing to use adequate contraception during the whole study period.
•16.Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an intervention

研究者

发起方

G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST

相似试验

招募中

2 期

Durvalumab (MEDI4736 ) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study

2024-511511-25-00UZ Leuven21

进行中（未招募）

2 期

Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)ung Cancer MetastaticLung Cancer MetastaticCancer - Lung - Non small cell

ACTRN12617001468314HMRC Clinical Trials Centre53

进行中（未招募）

1 期

EUCTR2017-001538-25-DEAIO-Studien-gGmbH128

进行中（未招募）

2 期

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASCarcinoma, Non-Small-Cell Lung

NCT06008093AstraZeneca103

已完成

2 期

A Phase II Study of Durvalumab and Tremelimumab in combination with Neoadjuvant Carboplatin and Paclitaxel in newly diagnosed women with advanced high grade Serous Ovarian, Fallopian Tube and Peritoneal Cancers iPRIME”.Fallopian tube cancerPeritoneal cancerCancer - Ovarian and primary peritonealOvarian cancer

ACTRN12618000109202Australia New Zealand Gynaecological Oncology Group (ANZGOG)75